Constructed CARs with a single universal tricistronic transgene were designed to recognize three different TAAs, namely, human epidermal growth factor receptor 2 (HER2), interleukin-13 receptor subunit alpha-2 (IL13Rα2), and ephrin-A2 (EphA2) to treat glioblastoma. Here, IL13RA2 is linked to glioblastoma.